ID   PI42A_HUMAN             Reviewed;         406 AA.
AC   P48426; B0YJ66; B4DGX2; D3DRV1; P53807; Q5VUX3;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   14-AUG-2001, sequence version 2.
DT   10-MAY-2017, entry version 150.
DE   RecName: Full=Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha;
DE            EC=2.7.1.149;
DE   AltName: Full=1-phosphatidylinositol 5-phosphate 4-kinase 2-alpha;
DE   AltName: Full=Diphosphoinositide kinase 2-alpha;
DE   AltName: Full=PIP5KIII;
DE   AltName: Full=Phosphatidylinositol 5-phosphate 4-kinase type II alpha;
DE            Short=PI(5)P 4-kinase type II alpha;
DE            Short=PIP4KII-alpha;
DE   AltName: Full=PtdIns(4)P-5-kinase B isoform;
DE   AltName: Full=PtdIns(4)P-5-kinase C isoform;
DE   AltName: Full=PtdIns(5)P-4-kinase isoform 2-alpha;
GN   Name=PIP4K2A; Synonyms=PIP5K2, PIP5K2A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 30-42;
RP   74-88; 93-112; 141-145; 254-259; 281-297 AND 383-406, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Placenta;
RX   PubMed=7852364; DOI=10.1074/jbc.270.7.2881;
RA   Boronenkov I.V., Anderson R.A.;
RT   "The sequence of phosphatidylinositol-4-phosphate 5-kinase defines a
RT   novel family of lipid kinases.";
RL   J. Biol. Chem. 270:2881-2884(1995).
RN   [2]
RP   SEQUENCE REVISION TO 298-310 AND 381-382.
RA   Boronenkov I.V.;
RL   Submitted (JAN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   VARIANT SER-251.
RC   TISSUE=Leukocyte;
RX   PubMed=7639683; DOI=10.1042/bj3090715;
RA   Divecha N., Truong O., Hsuan J.J., Hinchliffe K.A., Irvine R.F.;
RT   "The cloning and sequence of the C isoform of PtdIns4P 5-kinase.";
RL   Biochem. J. 309:715-719(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (FEB-2007) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Hippocampus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   CATALYTIC ACTIVITY.
RX   PubMed=9367159; DOI=10.1038/36621;
RA   Rameh L.E., Tolias K.F., Duckworth B.C., Cantley L.C.;
RT   "A new pathway for synthesis of phosphatidylinositol-4,5-
RT   bisphosphate.";
RL   Nature 390:192-196(1997).
RN   [10]
RP   FUNCTION.
RX   PubMed=18364242; DOI=10.1016/j.febslet.2008.03.022;
RA   Wilcox A., Hinchliffe K.A.;
RT   "Regulation of extranuclear PtdIns5P production by
RT   phosphatidylinositol phosphate 4-kinase 2alpha.";
RL   FEBS Lett. 582:1391-1394(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [12]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [13]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT THR-3 AND SER-14, CLEAVAGE OF INITIATOR METHIONINE
RP   [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [14]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-89 AND LYS-145, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [15]
RP   BIOPHYSICOCHEMICAL PROPERTIES, INTERACTION WITH PIP4K2B, SUBCELLULAR
RP   LOCATION, MUTAGENESIS OF GLY-131 AND TYR-138, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=20583997; DOI=10.1042/BJ20100341;
RA   Bultsma Y., Keune W.-J., Divecha N.;
RT   "PIP4Kbeta interacts with and modulates nuclear localization of the
RT   high-activity PtdIns5P-4-kinase isoform PIP4Kalpha.";
RL   Biochem. J. 430:223-235(2010).
RN   [16]
RP   REVIEW ON FUNCTION.
RX   PubMed=19896968; DOI=10.1016/j.advenzreg.2009.10.006;
RA   Clarke J.H., Wang M., Irvine R.F.;
RT   "Localization, regulation and function of type II phosphatidylinositol
RT   5-phosphate 4-kinases.";
RL   Adv. Enzyme Regul. 50:12-18(2010).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-14, CLEAVAGE OF INITIATOR METHIONINE [LARGE
RP   SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-3 AND SER-14, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
CC   -!- FUNCTION: Catalyzes the phosphorylation of phosphatidylinositol 5-
CC       phosphate (PtdIns5P) on the fourth hydroxyl of the myo-inositol
CC       ring, to form phosphatidylinositol 4,5-bisphosphate
CC       (PtdIns(4,5)P2). May exert its function by regulating the levels
CC       of PtdIns5P, which functions in the cytosol by increasing AKT
CC       activity and in the nucleus signals through ING2. May regulate the
CC       pool of cytosolic PtdIns5P in response to the activation of
CC       tyrosine phosphorylation. May negatively regulate insulin-
CC       stimulated glucose uptake by lowering the levels of PtdIns5P. May
CC       be involved in thrombopoiesis, and the terminal maturation of
CC       megakaryocytes and regulation of their size.
CC       {ECO:0000269|PubMed:18364242}.
CC   -!- CATALYTIC ACTIVITY: ATP + 1-phosphatidyl-1D-myo-inositol 5-
CC       phosphate = ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate.
CC       {ECO:0000269|PubMed:9367159}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=50 uM for phosphatidylinositol-5- phosphate
CC         {ECO:0000269|PubMed:20583997};
CC         Vmax=466 pmol/min/ug enzyme {ECO:0000269|PubMed:20583997};
CC   -!- SUBUNIT: Homodimer (By similarity). Interacts with PIP4K2B.
CC       Interaction with PIP4K2B may regulate localization to the nucleus.
CC       {ECO:0000250, ECO:0000269|PubMed:20583997}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}. Nucleus
CC       {ECO:0000269|PubMed:20583997}. Cytoplasm
CC       {ECO:0000269|PubMed:20583997}. Note=May translocate from the
CC       cytosol to the cell membrane upon activation of tyrosine
CC       phosphorylation. May translocate from the inner to the outer
CC       segments of the rod photoreceptor cells in response to light (By
CC       similarity). Localization to the nucleus is modulated by the
CC       interaction with PIP4K2B. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P48426-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P48426-2; Sequence=VSP_056458;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed ubiquitously, with high levels in
CC       the brain. Present in most tissues, except notably skeletal muscle
CC       and small intestine. {ECO:0000269|PubMed:7639683,
CC       ECO:0000269|PubMed:7852364}.
CC   -!- CAUTION: This protein was previously thought to be a
CC       phosphatidylinositol 4-phosphate 5-kinase. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U14957; AAA64835.2; -; mRNA.
DR   EMBL; S78798; AAB35041.1; -; mRNA.
DR   EMBL; AL513128; CAH72211.1; -; Genomic_DNA.
DR   EMBL; AL157707; CAH72211.1; JOINED; Genomic_DNA.
DR   EMBL; AL390318; CAH72211.1; JOINED; Genomic_DNA.
DR   EMBL; AK294817; BAG57933.1; -; mRNA.
DR   EMBL; EF445009; ACA06044.1; -; Genomic_DNA.
DR   EMBL; EF445009; ACA06045.1; -; Genomic_DNA.
DR   EMBL; AL157707; CAI39585.1; -; Genomic_DNA.
DR   EMBL; AL390318; CAI39585.1; JOINED; Genomic_DNA.
DR   EMBL; AL513128; CAI39585.1; JOINED; Genomic_DNA.
DR   EMBL; AL390318; CAH70526.1; -; Genomic_DNA.
DR   EMBL; AL157707; CAH70526.1; JOINED; Genomic_DNA.
DR   EMBL; AL513128; CAH70526.1; JOINED; Genomic_DNA.
DR   EMBL; CH471072; EAW86140.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW86141.1; -; Genomic_DNA.
DR   EMBL; BC018034; AAH18034.1; -; mRNA.
DR   CCDS; CCDS7141.1; -. [P48426-1]
DR   CCDS; CCDS81443.1; -. [P48426-2]
DR   PIR; A55967; A55967.
DR   PIR; S57217; S57217.
DR   RefSeq; NP_001316991.1; NM_001330062.1. [P48426-2]
DR   RefSeq; NP_005019.2; NM_005028.4. [P48426-1]
DR   RefSeq; XP_016871819.1; XM_017016330.1. [P48426-2]
DR   RefSeq; XP_016871820.1; XM_017016331.1. [P48426-2]
DR   UniGene; Hs.57079; -.
DR   PDB; 2YBX; X-ray; 2.56 A; A/B=35-405.
DR   PDBsum; 2YBX; -.
DR   ProteinModelPortal; P48426; -.
DR   SMR; P48426; -.
DR   BioGrid; 111322; 103.
DR   IntAct; P48426; 6.
DR   MINT; MINT-1507380; -.
DR   STRING; 9606.ENSP00000365757; -.
DR   ChEMBL; CHEMBL1795194; -.
DR   SwissLipids; SLP:000000855; -.
DR   iPTMnet; P48426; -.
DR   PhosphoSitePlus; P48426; -.
DR   BioMuta; PIP4K2A; -.
DR   DMDM; 18266879; -.
DR   OGP; P48426; -.
DR   EPD; P48426; -.
DR   MaxQB; P48426; -.
DR   PaxDb; P48426; -.
DR   PeptideAtlas; P48426; -.
DR   PRIDE; P48426; -.
DR   DNASU; 5305; -.
DR   Ensembl; ENST00000376573; ENSP00000365757; ENSG00000150867. [P48426-1]
DR   Ensembl; ENST00000545335; ENSP00000442098; ENSG00000150867. [P48426-2]
DR   GeneID; 5305; -.
DR   KEGG; hsa:5305; -.
DR   UCSC; uc001irl.5; human. [P48426-1]
DR   CTD; 5305; -.
DR   DisGeNET; 5305; -.
DR   GeneCards; PIP4K2A; -.
DR   HGNC; HGNC:8997; PIP4K2A.
DR   HPA; HPA065440; -.
DR   HPA; HPA068771; -.
DR   MalaCards; PIP4K2A; -.
DR   MIM; 603140; gene.
DR   neXtProt; NX_P48426; -.
DR   OpenTargets; ENSG00000150867; -.
DR   Orphanet; 99860; Precursor B-cell acute lymphoblastic leukemia.
DR   PharmGKB; PA162399615; -.
DR   eggNOG; KOG0229; Eukaryota.
DR   eggNOG; COG5253; LUCA.
DR   GeneTree; ENSGT00760000119184; -.
DR   HOGENOM; HOG000007832; -.
DR   HOVERGEN; HBG000072; -.
DR   InParanoid; P48426; -.
DR   KO; K00920; -.
DR   OMA; IVECHGV; -.
DR   OrthoDB; EOG091G0857; -.
DR   PhylomeDB; P48426; -.
DR   TreeFam; TF354315; -.
DR   BioCyc; MetaCyc:HS07693-MONOMER; -.
DR   Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane.
DR   Reactome; R-HSA-6811555; PI5P Regulates TP53 Acetylation.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-8847453; Synthesis of PIPs in the nucleus.
DR   SIGNOR; P48426; -.
DR   ChiTaRS; PIP4K2A; human.
DR   GeneWiki; PIP4K2A; -.
DR   GenomeRNAi; 5305; -.
DR   PRO; PR:P48426; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000150867; -.
DR   CleanEx; HS_PIP4K2A; -.
DR   ExpressionAtlas; P48426; baseline and differential.
DR   Genevisible; P48426; HS.
DR   GO; GO:0005776; C:autophagosome; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0052811; F:1-phosphatidylinositol-3-phosphate 4-kinase activity; TAS:Reactome.
DR   GO; GO:0016308; F:1-phosphatidylinositol-4-phosphate 5-kinase activity; NAS:UniProtKB.
DR   GO; GO:0016309; F:1-phosphatidylinositol-5-phosphate 4-kinase activity; EXP:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0035855; P:megakaryocyte development; IEA:Ensembl.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome.
DR   GO; GO:0006644; P:phospholipid metabolic process; TAS:Reactome.
DR   GO; GO:2000786; P:positive regulation of autophagosome assembly; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0010506; P:regulation of autophagy; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0014066; P:regulation of phosphatidylinositol 3-kinase signaling; TAS:Reactome.
DR   Gene3D; 3.30.800.10; -; 1.
DR   Gene3D; 3.30.810.10; -; 1.
DR   InterPro; IPR023610; PInositol-4-P-5-kinase.
DR   InterPro; IPR027483; PInositol-4-P-5-kinase_C.
DR   InterPro; IPR002498; PInositol-4-P-5-kinase_core.
DR   InterPro; IPR027484; PInositol-4-P-5-kinase_N.
DR   PANTHER; PTHR23086; PTHR23086; 1.
DR   Pfam; PF01504; PIP5K; 1.
DR   SMART; SM00330; PIPKc; 1.
DR   PROSITE; PS51455; PIPK; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Cell membrane; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Kinase; Membrane; Nucleotide-binding;
KW   Nucleus; Phosphoprotein; Polymorphism; Reference proteome;
KW   Transferase.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:22223895}.
FT   CHAIN         2    406       Phosphatidylinositol 5-phosphate 4-kinase
FT                                type-2 alpha.
FT                                /FTId=PRO_0000185465.
FT   DOMAIN       33    405       PIPK. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00781}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:22223895}.
FT   MOD_RES       3      3       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      14     14       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      89     89       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     145    145       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   VAR_SEQ       1     59       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056458.
FT   VARIANT       7      7       L -> I (in dbSNP:rs11813789).
FT                                /FTId=VAR_059764.
FT   VARIANT     251    251       N -> S (in dbSNP:rs10828317).
FT                                {ECO:0000269|PubMed:7639683}.
FT                                /FTId=VAR_024565.
FT   MUTAGEN     131    131       G->L: Abolishes catalytic activity; when
FT                                associated with F-138.
FT                                {ECO:0000269|PubMed:20583997}.
FT   MUTAGEN     138    138       Y->F: Abolishes catalytic activity; when
FT                                associated with L-131.
FT                                {ECO:0000269|PubMed:20583997}.
FT   CONFLICT    101    103       LRE -> CGK (in Ref. 3; AAB35041).
FT                                {ECO:0000305}.
FT   CONFLICT    109    109       D -> V (in Ref. 3; AAB35041).
FT                                {ECO:0000305}.
FT   CONFLICT    143    143       I -> M (in Ref. 3; AAB35041).
FT                                {ECO:0000305}.
FT   CONFLICT    177    178       QF -> HL (in Ref. 3; AAB35041).
FT                                {ECO:0000305}.
FT   CONFLICT    333    333       D -> E (in Ref. 3; AAB35041).
FT                                {ECO:0000305}.
FT   HELIX        36     52       {ECO:0000244|PDB:2YBX}.
FT   HELIX        63     67       {ECO:0000244|PDB:2YBX}.
FT   STRAND       69     80       {ECO:0000244|PDB:2YBX}.
FT   TURN         81     83       {ECO:0000244|PDB:2YBX}.
FT   STRAND       86     94       {ECO:0000244|PDB:2YBX}.
FT   HELIX        95    104       {ECO:0000244|PDB:2YBX}.
FT   HELIX       109    117       {ECO:0000244|PDB:2YBX}.
FT   STRAND      134    136       {ECO:0000244|PDB:2YBX}.
FT   STRAND      140    147       {ECO:0000244|PDB:2YBX}.
FT   HELIX       149    168       {ECO:0000244|PDB:2YBX}.
FT   TURN        169    171       {ECO:0000244|PDB:2YBX}.
FT   STRAND      178    186       {ECO:0000244|PDB:2YBX}.
FT   STRAND      189    197       {ECO:0000244|PDB:2YBX}.
FT   STRAND      202    204       {ECO:0000244|PDB:2YBX}.
FT   STRAND      207    212       {ECO:0000244|PDB:2YBX}.
FT   STRAND      215    217       {ECO:0000244|PDB:2YBX}.
FT   HELIX       223    226       {ECO:0000244|PDB:2YBX}.
FT   STRAND      228    230       {ECO:0000244|PDB:2YBX}.
FT   HELIX       235    240       {ECO:0000244|PDB:2YBX}.
FT   HELIX       249    268       {ECO:0000244|PDB:2YBX}.
FT   STRAND      271    273       {ECO:0000244|PDB:2YBX}.
FT   STRAND      275    282       {ECO:0000244|PDB:2YBX}.
FT   HELIX       283    291       {ECO:0000244|PDB:2YBX}.
FT   TURN        334    336       {ECO:0000244|PDB:2YBX}.
FT   STRAND      340    342       {ECO:0000244|PDB:2YBX}.
FT   STRAND      351    358       {ECO:0000244|PDB:2YBX}.
FT   STRAND      362    364       {ECO:0000244|PDB:2YBX}.
FT   HELIX       390    404       {ECO:0000244|PDB:2YBX}.
SQ   SEQUENCE   406 AA;  46225 MW;  5BAF0A27CC9EF376 CRC64;
     MATPGNLGSS VLASKTKTKK KHFVAQKVKL FRASDPLLSV LMWGVNHSIN ELSHVQIPVM
     LMPDDFKAYS KIKVDNHLFN KENMPSHFKF KEYCPMVFRN LRERFGIDDQ DFQNSLTRSA
     PLPNDSQARS GARFHTSYDK RYIIKTITSE DVAEMHNILK KYHQYIVECH GITLLPQFLG
     MYRLNVDGVE IYVIVTRNVF SHRLSVYRKY DLKGSTVARE ASDKEKAKEL PTLKDNDFIN
     EGQKIYIDDN NKKVFLEKLK KDVEFLAQLK LMDYSLLVGI HDVERAEQEE VECEENDGEE
     EGESDGTHPV GTPPDSPGNT LNSSPPLAPG EFDPNIDVYG IKCHENSPRK EVYFMAIIDI
     LTHYDAKKKA AHAAKTVKHG AGAEISTVNP EQYSKRFLDF IGHILT
//
